Interestingly, Wang et al. screened FDA-approved drugs and identified thiram as a potent inhibitor of the TRMT6/TRMT61A methyltransferase complex, which suppressed liver cancer stem cell self-renewal and reduced oncosphere formation in HCC cell lines in vitro, as well as inhibited tumor growth in vivo [43]. This evidence concerns the gene TRMT6 and hepatocellular carcinoma.